Back to results
US 6,485,925 B1Granted
Anthrax lethal factor is a MAPK kinase protease
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsNicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
Life of this patent
Estimating the term…
Abstract
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
Claims15
An in vivo method for screening modulators of lethal factor (LF) mitogen activated protein kinase kinase (MAPKK) protease activity, the method comprising the steps of:
- (i) contacting a living cell with LF, wherein the LF has MAPKK protease activity;
- (ii) contacting the cell with substances suspected of having the ability to modulate MAPKK protease activity;
- (iii) assaying for the level of LF MAPKK protease activity;
- (iv) assaying for the level of LF MAPKK protease activity in the absence of said substances suspected of having the ability to modulate LF MAPKK protease activity;
- and
- (v) comparing the LF MAPKK protease activity in step (iii) to that in step (iv), whereby substances are identified as modulators when the LF MAPKK activity in step (iii) is lower than the LF MAPKK activity in step (iv).
3 more elements
Dependencies are inferred from the claim text.